Vorteile bioidentischer Sexualhormone in der systemischen menopausalen Hormontherapie

Manson JE et al (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 310(13):1353–1368

Birkhäuser M (2018) Menopausale Hormontherapie aus heutiger Sicht. Gynäkologie 3:18–22

Bhavnani BR, Staczyk FZ (2014) Pharmacology of conjugated equine estrogens: efficacy, safety and mechanism of action. J Steroid Biochem Mol Biol 142:16–29

Whelan AM, Jurgens TM, Trinacty M (2011) Defining bioidentical hormones for menopause related symptoms. Pharm Pract 9(1):16–22

Pinkerton JA (2014) What are the concerns about custom-compounded bioidentical hormone therapy? Menopause 21(12):1298–1300

Baber RJ, Panay N, Fenton A (2016) 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 19(2):109–150

De Villiers TJ et al (2016) Revised global consensus statement on menopausal hormone therapy. Climacteric 19(4):313–315

Hickey M, Elliot J, Davison SL et al (2012) Hormone replacement therapy. BMJ 334:e763

Windler E, Ortmann O (2018) 18 Jahre Mortalitätsdaten zu HRT – mehr Sicherheit für die Anwendung. Frauenarzt 59(9):688–689

Manson JE et al (2017) WHI investigators: menopausal hormone therapy and long-term all cause and cause specific mortality: the Women’s Health Initiative randomized trials. JAMA 318(19):927–938

Hodis N et al (2016) Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 374(13):1221–1231

Schierbeck LL et al (2012) Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 345:e6409

L’Hermite M (2017) Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal. Climacteric 4:331–338

Morville R (1982) The bioavailability of natural progesterone given by mouth. Measurement of steroid concentrations in plasma, endometrium and breast tissue. J Gynecol Obstet Biol Reprod 11:355–363

The Writing Group for the PEPI Trial (1996) Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 275(5):370–375

Fournier A, Dossus L, Mesrine S, Vilier A, Boutron-Ruault MC, Clavel-Chapelon F, Chabbert-Buffet N (2014) Risks of endometrial cancer associated with different hormone replacement therapies in the E3N Cohort, 1992–2008. Am J Epidemiol 180(5):508–517

Mueck AO (2015) Systemische Progesterontherapie – transdermal? Gynäkologische Endokrinologie 13:50–56

Stute P, Neulen J, Wildt L (2016) The impact of micronized progesterone on the endometrium: a systematic review. Climacteric 19(4):316–328

Bakken K et al (2011) Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European prospective investigation into cancer and nutrition. Int J Cancer 128(1):144–156